On Jan 20, 2022 ImmPACT Bio USA closed a Series B round and raised $111,000,000 from Bukwang Pharmaceutical Co, Decheng Capital, Foresite Capital, Novartis Venture Fund, OrbiMed, RM Global Partners, Surveyor Capital, venBio Partners, featuring lead investors Decheng Capital, Foresite Capital, Surveyor Capital, venBio Partners.

About the company: ImmPACT Bio USA is located at United States, North America.
“”

Company website: http://www.immpact-bio.com